Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Major Shareholder Sells $2,484,865.85 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Rating) major shareholder Xi L.P. Canaan sold 115,307 shares of the business’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $21.55, for a total value of $2,484,865.85. Following the transaction, the insider now directly owns 9,303,299 shares in the company, valued at approximately $200,486,093.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Xi L.P. Canaan also recently made the following trade(s):

  • On Tuesday, September 20th, Xi L.P. Canaan sold 148,670 shares of Day One Biopharmaceuticals stock. The stock was sold at an average price of $19.51, for a total value of $2,900,551.70.
  • On Wednesday, September 14th, Xi L.P. Canaan sold 106,111 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $23.68, for a total value of $2,512,708.48.

Day One Biopharmaceuticals Stock Down 3.1 %

Day One Biopharmaceuticals stock opened at $17.74 on Friday. Day One Biopharmaceuticals, Inc. has a twelve month low of $5.44 and a twelve month high of $28.35. The stock has a 50 day moving average of $21.94 and a two-hundred day moving average of $15.02.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.11). Analysts predict that Day One Biopharmaceuticals, Inc. will post -2.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on DAWN shares. Piper Sandler upped their price target on Day One Biopharmaceuticals from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, June 20th. Wedbush upped their price target on Day One Biopharmaceuticals from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, June 13th.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Amalgamated Bank purchased a new stake in shares of Day One Biopharmaceuticals in the first quarter valued at $30,000. ACG Wealth acquired a new position in Day One Biopharmaceuticals in the second quarter valued at $32,000. TCI Wealth Advisors Inc. acquired a new position in Day One Biopharmaceuticals in the second quarter valued at $35,000. Quantbot Technologies LP acquired a new position in shares of Day One Biopharmaceuticals during the second quarter worth about $51,000. Finally, UBS Group AG acquired a new position in shares of Day One Biopharmaceuticals during the second quarter worth about $69,000. Hedge funds and other institutional investors own 95.40% of the company’s stock.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Further Reading

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.